How Integral Diagnostics (ASX: IDX) Is Transforming Imaging with AI
Integral Diagnostics is one of Australia and New Zealand’s largest diagnostic imaging providers, operating across a network of radiology clinics and serving both metropolitan and regional populations. With a workforce of over 2,800 and more than 1.3 million scans performed in the first half of FY25 alone, IDX plays a critical role in healthcare delivery, offering services such as MRI, CT, ultrasound, and nuclear medicine. In recent years, artificial intelligence has become central to its operating model not to replace radiologists, but to enhance their capabilities.
AI is already being used to support complex image reporting across high-volume modalities like MRI and CT, where it assists in flagging anomalies, accelerating reporting, and improving consistency. These tools reduce the cognitive load on radiologists and help deliver faster turnaround for referrers, especially important in regional areas with workforce shortages. The adoption of AI has become more structured with the development of IDXt, a custom-built teleradiology platform. IDXt supports 24/7 remote reporting by integrating intelligent automation into image transfer, workflow prioritisation, and report standardisation across multiple geographies.
AI in Action: Platform, People, and Performance
Beyond technology, IDX is building an organisation around AI-enabled workflows. It invested over $14.8 million into growth initiatives in the half year, including AI-supported systems and radiologist training. Following its merger with Capitol Health, the company is transitioning toward a fully integrated “One Team” model, streamlining processes across all its practices and standardising reporting. This unified approach supports consistent quality, even as scan volumes rise.
AI also plays a growing role in the company’s front-end experience. Referrers now benefit from upgraded digital portals and faster notifications, which help speed up clinical decision-making. The enhanced systems improve not just operational efficiency but strengthen the relationship between IDX and its referring doctors - a key driver of recurring volumes.
Financial Highlights from 1H FY25:
- Revenue rose 7.8% to $249.4 million
- Operating EBITDA increased 8.2% to $46.8 million
- Operating NPAT grew 31.9% to $9.8 million
- Free cash flow improved 22.7% to $29.4 million
Looking ahead, IDX is positioned to benefit from upcoming healthcare trends, including the National Lung Cancer Screening Program launching in July 2025, and MRI deregulation, both expected to boost scan volumes. With AI systems already embedded across operations, the company is well-positioned to absorb growth efficiently while maintaining diagnostic quality.
In a sector where accuracy, speed, and scalability are becoming non-negotiable, IDX is using AI not to replace its people but to equip them for the future.
How ResMed (ASX: RMD) Is Using AI to Breathe New Life into Healthcare
ResMed is a global leader in sleep and respiratory care, offering cloud-connected devices and digital health platforms that serve millions of patients worldwide. With over 160 million lives digitally supported, ResMed is going beyond traditional hardware — it’s building a connected, intelligent care ecosystem powered by artificial intelligence. From personalising therapy to optimising provider workflows, AI is transforming how ResMed delivers care at scale.
AI at the Core of Respiratory Therapy
Artificial intelligence is central to how ResMed’s devices and platforms operate. Its connected products including AirSense and AirCurve - collect and analyse nightly breathing data, which syncs directly with myAir for patients and AirView for clinicians. AI algorithms assess compliance trends, detect therapy issues, and provide tailored alerts or nudges to improve patient adherence.
This real-time feedback loop helps patients remain engaged while giving doctors a clearer view of progress without requiring in-person visits. Especially for sleep apnea and COPD where continuous usage is key AI-driven monitoring enhances outcomes and reduces hospitalisation risk.
Smarter Software for Smarter Care
Beyond devices, ResMed’s AI capabilities extend to its software-as-a-service (SaaS) portfolio, which includes Brightree and MatrixCare. These platforms support home health, hospice, and long-term care providers by automating complex workflows. AI assists with clinical documentation, insurance claim reviews, and care coordination allowing providers to serve more patients efficiently in resource-constrained environments.
With healthcare systems worldwide facing staffing and cost pressures, this AI-driven automation plays a vital role in improving throughput without compromising care quality.
AI Behind the Scenes
Artificial intelligence also powers operational decision-making within ResMed. In FY25, the company has implemented predictive analytics across its global supply chain, enabling better alignment between production and market demand. As demand patterns stabilise after the pandemic surge, smart forecasting tools help ResMed reduce lead times, manage inventories, and optimise delivery critical for maintaining high service levels across markets.
Financial Highlights from Q3 FY25:
- Revenue grew 7% YoY to US$1.20 billion
- Operating profit increased 5% to US$333 million
- Gross margin expanded by 50 bps to 56.4%
- Free cash flow reached US$277 million, up from US$54 million
- Quarterly dividend declared at US$0.48 per share
These figures reflect both stabilising demand and the operational efficiency gains unlocked by AI across segments.
Scaling into the Future of Digital Respiratory Care
ResMed’s long-term vision is to become the global leader in digital health for chronic respiratory disease management. It is actively expanding AI features within its AirView for Ventilation platform, which allows clinicians to access real-time, detailed patient data remotely especially useful for managing high-acuity cases at home. With new reimbursement models and digital-first healthcare ecosystems emerging globally, the ability to deliver scalable, AI-backed care is becoming a competitive edge.
In a world where patient loads are rising and clinical resources are stretched, ResMed’s AI-led model offers not just efficiency but a smarter, more responsive way to deliver better breathing and better living.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
